Insider Move at Charles River Labs: Director Cashes In on Company Stock
I'm LongbridgeAI, I can summarize articles.Charles River Labs director Nancy C. Andrews sold 573 shares worth $163,442 on August 20, 2026. This insider move coincides with positive market reactions to the company's Q2 earnings beat, margin expansion, and raised guidance. Despite analyst upgrades driven by recovering demand and strong DSA bookings, TipRanks' AI Analyst Spark rates CRL as Neutral due to recent financial losses and negative P/E, though technical signals remain bullish.
New insider activity at Charles River Labs ( (CRL) ) has taken place on August 20, 2026.
Director Nancy C. Andrews has recently reduced her stake in Charles River Laboratories, selling 573 shares of the company’s stock. The transaction, valued at $163,442, highlights a notable insider move that may draw attention from investors tracking executive and director trading activity.
Charles River Labs shares moved higher over the last day as investors reacted to a Q2 beat, margin expansion and a guidance raise that signaled a return to modest organic growth. Management’s emphasis on robust DSA bookings, a rising backlog, improved free cash flow outlook and strong manufacturing margins helped offset concerns over RMS softness, higher corporate costs and tax headwinds.
Analysts raised price targets largely on evidence that discovery and safety assessment demand is sustainably recovering, supported by healthy biotech funding and stable pharma activity. The upgraded outlook for 2026 EPS and revenue, plus visibility from a 1.19 DSA book‑to‑bill and strategic initiatives like AI‑enabled partnerships and portfolio optimization, reinforced confidence in more durable top‑ and bottom‑line growth despite ongoing segment and funding pressures.
Spark’s Take on CRL Stock
According to Spark, TipRanks’ AI Analyst, CRL is a Neutral.
The score is held back primarily by weakened financial performance (losses and steep TTM revenue decline) and limited valuation support due to negative earnings (negative P/E). Offsetting factors include strong technical momentum (price well above key moving averages with positive MACD) and a constructive earnings-call setup with raised FY2026 guidance and expected margin expansion, though execution and timing risks (RMS softness, back-loaded benefits, and higher corporate costs/tax headwind) remain.
To see Spark’s full report on CRL stock,
click here.
More about Charles River Labs
YTD Price Performance: 45.38%
Average Trading Volume: 896,432
Technical Sentiment Signal: Buy
Current Market Cap: $13.33B